AstraZeneca plc (NASDAQ: AZN) is proposing a Harmonized Listing Structure for its ordinary shares on the LSE, Nasdaq Stockholm, and NYSE. This upgrade involves a direct listing on the NYSE, allowing shareholders to trade across all three exchanges. The move aims to attract global investors and maintain the company’s UK listing status.

High-level results from AstraZeneca’s DESTINY-Breast05 Phase 3 trial show Enhertu significantly improved invasive disease-free survival in HER2-positive early breast cancer patients. A previous trial, DESTINY-Breast11, also demonstrated positive results. Overall survival data will be assessed later. AZN stock was up 0.84% premarket at $74.38.

The proposed listing structure alleviates concerns for UK investors, as AstraZeneca, London’s top company, remains UK-listed. The move avoids fears of a potential shift to the US and supports London’s stock market. AstraZeneca aims to engage a wider range of global investors and secure a strong future for shareholders.

Read more at Yahoo Finance: AstraZeneca Moves From ADRs To NYSE Listing